Sustainable Diets and Cardiometabolic Health
- Conditions
- Cardiometabolic Diseases
- Registration Number
- NCT07189676
- Lead Sponsor
- University of Copenhagen
- Brief Summary
This study aims to investigate the effects of sustainable diets on traditional and novel cardiometabolic risk factors.
The primary objective is:
• To test the effects of a sustainable diet on traditional cardiometabolic risk factors, specifically, a metabolic health score.
The secondary objectives are:
* To test the effects of sustainable diets on blood lipids, inflammatory markers, glucose markers, and anthropometric and body composition markers.
* To test the effect of sustainable diets on circulating metabolomic profiles.
* To test the effects of sustainable diets on circulating proteomic profiles.
Participants will receive dietary interventions of a sustainable health diet, namely the PHD diet (Planetary Health Diet), an ovo-lacto-vegetarian diet, or a habitual diet following general recommendations for a healthy diet without advice on consumption of animal products. The three-arm parallel RCT will involve adults (45-70 years old) at cardiovascular risk.
The primary hypothesis is that targeted interventions to adopt sustainable diets will have beneficial effects on cardiometabolic biomarkers, metabolomic, and proteomic profiles, compared to the habitual diet in individuals at cardiovascular risk.
- Detailed Description
Background: To promote sustainable diets for planetary and human health, the EAT-Lancet Commission called for a global dietary transformation by 2050, advocating a dietary pattern shift to align food systems with environmental sustainability and human health. The Planetary Health Diet (PHD) promotes a plant-based approach, emphasizing the consumption of whole grains, fruits, vegetables, nuts, and legumes, and limited amounts of seafood and poultry, while discouraging excessive intake of red and processed meat, added sugar, refined grains, and starchy vegetables. Despite the promotion of the popular EAT-Lancet diet, there is no Randomized Controlled Trial (RCT) evaluating the impact of this pattern on established and novel cardiometabolic biomarkers. The trial design addresses the recognized lack of RCTs evaluating changes in multi-omic profiles by adhering to different dietary interventions; the lack of RCTs on sustainable diets that consider environmental aspects; and overcome limitations of potential reverse causation and other biases from observational studies.
Investigation plan: Participants will be randomized to receive advice on changes in the overall dietary pattern from specialized dietitians. Participants in the PHD diet group will be guided to follow the EAT-Lancet recommendations adapted to be nutritionally adequate and culturally acceptable in Denmark (a high-quality plant-based diet with a low allowance of intake of eggs, dairy, chicken, and fish, but strictly avoiding red and processed meat). Participants in the vegetarian diet group will be advised to adhere to a stricter plant-based diet with an intake of eggs and dairy but avoiding chicken, fish, and red and processed meat, and no recommendations on food quantity or the environment. The two interventions will be compared with the control group, where participants will follow their habitual diet without specific advice on the consumption of animal products. The present RCT is not a weight loss trial, thus no total calorie restriction will be advised, and physical activity will not be promoted. A maximum alcohol consumption limited to 100 grams/week for men and women drinkers will be allowed.
Dietary considerations: The comparisons will allow us to address the unanswered question of whether the inclusion of moderate amounts of animal-based products in the context of a climate-friendly diet is superior to a stricter vegetarian diet. Vegan diets were not considered because of the difficulty in adherence in European settings and the potential for micronutrient deficiencies. The higher between-group contrast, considering both health and environmental impact is expected to be found for PHD vs control group.
The study will include an information meeting, screening visit, baseline visit, two visits during the intervention (1 month and 3 months), and a final visit at 6 months. Additionally, two group visits (at 2 and 4 months) will be conducted. Outcome parameters (a metabolic health score and its components) will be measured using blood samples obtained at baseline, 3 months, and final visit. Urine samples will be collected for the research biobank at the baseline, 1 month, 3 months, and final visit. Fecal samples will be collected at baseline and the final visit. Participants will wear continuous glucose monitors (CGM) for 10 days at baseline and at the end of follow-up.
Participants will have access to a study app that will include a timeline of the study, study materials including dietary recommendations, meal planners and recipes according to the intervention group, and instructions for collecting biosamples. Participants will also use the app to respond to self-reported questionnaires. Food boxes containing targeted products for each intervention will be distributed to participants at baseline, 1 month, and 3 months.
Participants will attend two group visits (5-15 participants), where they will receive educational material, information about the science behind the trial and have the opportunity to share experiences with their peers.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 180
- Adults (males and females) between 45 and 70 years of age at the time of inclusion.
- Participants must have at least two metabolic alterations: 1) Waist Circumference (WC) >102 cm (males) or >88 cm (females); 2) self-reported medication for blood pressure or blood pressure >130/85 mmHg; 3) self-reported prediabetes or non-fasting plasma glucose 140-199 mg/dL (prediabetes); 4) self-reported lipid-lowering medication or diagnosis of impaired blood lipids (triglycerides: ≥ 150 mg/dL; and HDL: men: < 40 mg/dL and women: < 50 mg/dL).
- Participants are not institutionalized, able to read and provide consent before participation, and willing to attend in-person visits at the study site.
- Participants should have access to a smartphone and computer, or tablet and must be internet-literate.
- Understand Danish both in writing and when spoken.
- Participants with any serious illness or history of cancer within the past 5 years (except adequately treated localized basal cell skin cancer or in situ uterine cervical cancer).
- Diagnosed with diabetes mellitus, CVD event (myocardial infarction, revascularization procedure, or stroke), or atrial fibrillation.
- Participants with diagnosed psychiatric conditions or cognitive impairment.
- Current smokers including all kinds of nicotine-containing products.
- BMI >35 kg/m2.
- Known or suspected abuse of alcohol or recreational drugs. Regular alcohol consumption exceeding the Danish national guidelines (i.e., more than 10 standard drinks per week or more than 4 drinks on any single day) will be excluded.
- Pregnancy or planning a pregnancy in the next year.
- Not willing to consume chicken and fish or not willing to make dietary changes related to the intervention.
- Participants with multiple food allergies that could hinder adherence to the intervention.
- Any other issue that makes the project responsible (PI or medical responsible) doubt the eligibility of the volunteer.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Changes in metabolic health score Baseline, 3 and 6 months A metabolic health score that summarizes clinical biomarkers from main pathways associated with CVD: triglycerides, HDL-c, fasting plasma glucose, systolic and diastolic blood pressure, and high sensitive C-reactive protein (hs-CRP) (as a marker of inflammation). A Z-score will be calculated for each variable. HDL-cholesterol standardized values will be multiplied by -1 to be directly proportional to the cardiometabolic risk. The final score will be determined as the average of the individual component Z-scores. Thus, the metabolic health score is a continuous variable with a mean of 0 and a standard deviation of 1; higher scores indicate higher risk
- Secondary Outcome Measures
Name Time Method Changes in low-lipoprotein-cholesterol concentrations (LDL-c) Baseline, 3 and 6 months Venous blood samples will be collected. LDL-c will be measured in fasting samples.
Changes in high-lipoprotein-cholesterol concentration (HDL-c) Baseline, 3 and 6 months Venous blood samples will be collected. HDL-c will be measured in fasting samples.
Changes in triglycerides concentration Baseline, 3 and 6 months Venous blood samples will be collected. Triglycerides will be measured in fasting samples.
Changes in Apoliprotein A1 (ApoA1) concentration Baseline, 3 and 6 months Venous blood samples will be collected. ApoA1 will be measured in fasting samples.
Changes in Apoliprotein B (ApoB) concentration Baseline, 3 and 6 months Venous blood samples will be collected. ApoB will be measured in fasting samples.
Changes in fasting glucose Baseline, 3 and 6 months Fasting glucose will be measured in blood
Changes in insuline Baseline, 3 and 6 months insulin levels will be measured in blood
Changes in HA1c Baseline, 3 and 6 months Concentration levels of hemoglobin A1c will be measured in blood
Changes in continuous glucose monitor (CGM) measures Baseline and 6 months CGM will be used to measure interstitial glucose in free-living conditions over 10 days.
Changes in high-sensitive C-reactive protein concentrations Baseline, 3 and 6 months High-sensitive C-reactive protein concentration in fasting blood samples will be measured
Changes in Interleukin 6 (IL-6) concentrations Baseline, 3 and 6 months Interleukin 6 concentration in fasting blood samples will be measured.
Changes in systolic blood pressure Baseline, 3 and 6 months Measurements should be preceded by at least 5 minutes of rest in a quiet setting without distractions. Participants should be seated comfortably, with their arms resting and maintaining silence while the measurements are being taken. Two measures are taken, and the mean of the two measures is used. If there is a difference \>5 mmHg between the two measurements, a third measure will be taken, and the two closer measurements will be used to calculate the mean.
Changes in distastolic blood pressure Baseline, 3 and 6 months Measurements should be preceded by at least 5 minutes of rest in a quiet setting without distractions. Participants should be seated comfortably, with their arms resting and maintaining silence while the measurements are being taken. Two measures are taken, and the mean of the two measures is used. If there is a difference \>5 mmHg between the two measurements, a third measure will be taken, and the two closer measurements will be used to calculate the mean.
Changes in heart rate Baseline, 3 and 6 months Measurements should be preceded by at least 5 minutes of rest in a quiet setting without distractions. Participants should be seated comfortably, with their arms resting and maintaining silence while the measurements are being taken. Two measures are taken, and the mean of the two measures is used.
Changes in body weight Baseline, 3 and 6 months Body weight (kg) will be measured with minimal clothing. The same calibrated equipment will be used for the respective measurements, and all study staff involved will be trained in handling the equipment and performing the measurements.
Changes in waist circumference Baseline, 3 and 6 months The waist circumference will be measured using a flexible anthropometric tape (cm)
Changes in body mass index Baseline, 3 and 6 months The body mass index will be calculated by dividing the weight (kg) by the square of height (m\^2).
Changes in fat (%) Baseline, 3 and 6 months Dual-energy X-ray Absorptiometry (DXA) scan will be performed in the morning in order to measure fat percentage (%). Participants are asked to meet fasting during the preceding 8 hours and to drink 400 mL of water before the measurement to ensure fluid balance.
Changes in lean mass Baseline, 3 and 6 months Dual-energy X-ray Absorptiometry (DXA) scan will be performed in the morning in order to measure lean mass. Participants are asked to meet fasting during the preceding 8 hours and to drink 400 mL of water before the measurement to ensure fluid balance.
Changes in plasma metabolome Baseline, 3 and 6 months Targeted metabolomics analysis will be conducted on plasma samples using a combination of liquid chromatography and high-resolution mass spectrometry. The concentration of 400 metabolites, including amino acids, acylcarnitines, tricarboxylic acid cycle metabolites, bile acids, purines, and pyrimidines will be measured.
Changes in plasma lipidome Baseline, 3 and 6 months Targeted lipidomic analysis will also be carried out in plasma samples using liquid chromatography coupled with a trapped ion mobility spectroscopy time of flight mass spectrometer (LC-TIMS-TOF-MS). The concentration of 300 lipids will be annotated.
Changes in plasma proteome Baseline, 3 and 6 months The Olink® Explore HT platform is a high-throughput, multiplex immunoassay platform intended to measure the relative concentration of proteins in liquid biopsies. The platform uses Olink's PEA™ technology coupled with a Next Generation Sequencing (NGS) readout method (NovaSeq6000 S4). The Olink® Explore HT analysis measures 5416 proteins using 2mL of sample volume with a specificity of 99.5% and negligible cross-reactivity. The outputted raw counts data is first processed using Olink® Explore Pre-processing software ngs2counts (version 4.5.0) and then quality-controlled using Olink® NPX Explore HT software (version 2.2.1) before generation of the Normalized Protein eXpression (NPX) values, Olink's unit of protein expression level in a log2 scale.
Trial Locations
- Locations (1)
University of Copenhagen
🇩🇰Copenhagen, Denmark
University of Copenhagen🇩🇰Copenhagen, Denmark